We advised LSP (Life Sciences Partners) with its investment in the Series B financing round of ViCentra, a company developing and commercializing an insulin pump system for diabetes patients.  With its Kaleido insulin pump, ViCentra aims to reduce the impact that diabetes can have on daily life. The syndicate, led by LSP with participation from existing investor INKEF, will invest EUR 10 million. The funding will support European commercialization of the Kaleido system and preparations for US market entry.